Luminary Therapeutics
Clinical trials sponsored by Luminary Therapeutics, explained in plain language.
-
Can a new immune cell therapy outsmart resistant blood cancers?
Cure Not yet recruitingThis Phase 2 trial is testing an experimental therapy called LMY-920, which uses a patient's own immune cells (T cells) engineered to recognize and attack cancer cells through a protein called BAFF. The study aims to see if this treatment can shrink tumors or eliminate signs of c…
Phase 2 • Sponsor: Luminary Therapeutics • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Can engineered immune cells tame stubborn autoimmune diseases?
Disease control Not yet recruitingThis phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…
Phase 1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Not yet recruitingThis phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …
Phase 1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC